Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,369 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
Schwartz H, Krause R, Sahba B, Haber M, Weissfeld A, Rose P, Siepman N, Freston J. Schwartz H, et al. Among authors: Rose P. Am J Gastroenterol. 1998 Apr;93(4):584-90. doi: 10.1111/j.1572-0241.1998.169_b.x. Am J Gastroenterol. 1998. PMID: 9576452 Clinical Trial.
., and 2% (1 of 53) of those receiving lansoprazole monotherapy (p < or = 0.05, triple therapy vs each dual therapy and each dual therapy vs monotherapy). ...

., and 2% (1 of 53) of those receiving lansoprazole monotherapy (p < or = 0.05, triple therapy vs each dual therapy and each dual

Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2-receptor antagonists.
Kovacs TO, Campbell D, Richter J, Haber M, Jennings DE, Rose P. Kovacs TO, et al. Among authors: Rose P. Aliment Pharmacol Ther. 1999 Jul;13(7):959-67. doi: 10.1046/j.1365-2036.1999.00569.x. Aliment Pharmacol Ther. 1999. PMID: 10383532 Clinical Trial.
At Month 12, significantly (P < 0.001) more lansoprazole 15 mg patients (70%) and lansoprazole 30 mg patients (85%) remained healed. ...

At Month 12, significantly (P < 0.001) more lansoprazole 15 mg patients (70%) and lansoprazole 30 mg patients (85%) remained heale

A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori.
Fennerty MB, Kovacs TO, Krause R, Haber M, Weissfeld A, Siepman N, Rose P. Fennerty MB, et al. Among authors: Rose P. Arch Intern Med. 1998 Aug 10-24;158(15):1651-6. doi: 10.1001/archinte.158.15.1651. Arch Intern Med. 1998. PMID: 9701099 Clinical Trial.
At 4 to 6 weeks after the end of therapy, H pylori was eradicated in 85% (96/ 113) of the patients receiving 14-day triple therapy and in 84% (103/123) of those receiving 10-day triple therapy by per-protocol analysis (95% confidence interval for treatment group differences, -10. …
At 4 to 6 weeks after the end of therapy, H pylori was eradicated in 85% (96/ 113) of the patients receiving 14-day triple therapy and in 84 …
Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healed gastric ulcer.
Kovacs TO, Campbell D, Haber M, Rose P, Jennings DE, Richter J. Kovacs TO, et al. Among authors: Rose P. Dig Dis Sci. 1998 Apr;43(4):779-85. doi: 10.1023/a:1018818115047. Dig Dis Sci. 1998. PMID: 9558034 Clinical Trial.
As compared to placebo, a significantly (P < 0.001) higher percentage of patients treated with lansoprazole 15 mg (83%) and lansoprazole 30 mg (93%) with healed gastric ulcer disease remained healed at month 12. ...

As compared to placebo, a significantly (P < 0.001) higher percentage of patients treated with lansoprazole 15 mg (83%) and lansop

Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection.
Harford W, Lanza F, Arora A, Graham D, Haber M, Weissfeld A, Rose P, Siepman N. Harford W, et al. Among authors: Rose P. Helicobacter. 1996 Dec;1(4):243-50. doi: 10.1111/j.1523-5378.1996.tb00046.x. Helicobacter. 1996. PMID: 9398875 Clinical Trial.
By per-protocol analysis, H. pylori infection was cured in 57% of those treated with lansoprazole twice daily plus amoxicillin and in 67% of those treated with lansoprazole three times daily plus amoxicillin, compared with 0% treated with lansoprazole alone or amoxicillin alone ( …
By per-protocol analysis, H. pylori infection was cured in 57% of those treated with lansoprazole twice daily plus amoxicillin and in 67% of …
Safety profile of Lansoprazole: the US clinical trial experience.
Freston JW, Rose PA, Heller CA, Haber M, Jennings D. Freston JW, et al. Among authors: Rose PA. Drug Saf. 1999 Feb;20(2):195-205. doi: 10.2165/00002018-199920020-00008. Drug Saf. 1999. PMID: 10082075 Review.
Special Edition: COVID-19 Guest Editorial.
Rose P, Levine WN. Rose P, et al. J Am Acad Orthop Surg. 2020 Jun 1;28(11):435. doi: 10.5435/JAAOS-D-20-00337. J Am Acad Orthop Surg. 2020. PMID: 32459408 No abstract available.
1,369 results
Jump to page
Feedback